Sells API business to subsidiary, brings in PE investors for up to Rs 700 cr growth

Listed Co AcquisitionCore Business DivestedMarquee Jv AnnouncedStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹2847.40

prior close

₹2863.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-1.5% vs market

Pharmaceuticals peers, median of 162sector-0.7%-1.4% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.4

15m

-0.9

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.6-1.5-0.7-1.4

Next day

-2.8+0.5-3.3-0.5-2.3

-3.1+1.9-5.0+0.2-3.3

-4.0+2.3-6.3+0.1-4.2

-4.3+3.6-7.9+0.5-4.8

-6.6+4.0-10.6+0.7-7.3

-7.4+4.0-11.4+1.4-8.8

15d

-6.8+4.9-11.7+0.4-7.2

-7.1+5.9-13.1+1.7-8.8

+6.8+4.8+2.0+2.7+4.2

-10.6pendingpending-2.4-8.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved three deals: 1) Slump sale of API business to wholly owned subsidiary RPG Active Pharma for about Rs 33.55 cr. API contributed Rs 95.06 cr (13.54 percent) to FY26 revenue. 2) India Life Sciences Fund IV and Vistaject Fund to invest Rs 243.33 cr for 40 percent stake in RPGAP, with total commitment up to Rs 700 cr for API growth. 3) RPGAP to acquire 100 percent of Actis Generics for Rs 80 cr cash. Sale expected by Sept 30, 2026.

Likely market impact

API business (13.5 percent of revenue) moves to subsidiary backed by PE investors with up to Rs 700 cr commitment; parent shareholding unchanged.